文献速递甲状腺核医学核素与放射性配体治疗

分化型甲状腺癌淋巴结复发:淋巴结清扫术后辅助放射性碘治疗的作用

Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2016-12-14

该回顾性研究评估了淋巴结清扫术后辅助放射性碘治疗对分化型甲状腺癌淋巴结复发患者无进展生存和总生存的影响,纳入113例患者(64例接受放射性碘治疗)。中位随访5.7年,27例进展、13例死亡。仅促甲状腺激素抑制下甲状腺球蛋白≥1 ng/ml的患者接受放射性碘治疗后无进展生存和总生存更优,多因素分析显示放射性碘是唯一与无进展生存独立相关的因素(HR 0.36)。

要点

  • 在淋巴结清扫术后,促甲状腺激素抑制下甲状腺球蛋白≥1 ng/ml的复发患者接受放射性碘治疗与更好的无进展生存和总生存相关。
  • 促甲状腺激素抑制下甲状腺球蛋白<1 ng/ml的患者未观察到放射性碘治疗的效果。

核心结论

  • 对于分化型甲状腺癌淋巴结复发患者,淋巴结清扫术后放射性碘治疗仅在促甲状腺激素抑制下甲状腺球蛋白≥1 ng/ml的患者中与更好的无进展生存显著相关。

研究设计与样本

  • 回顾性评估113例因疾病复发接受淋巴结清扫的分化型甲状腺癌患者,所有患者既往均行全甲状腺切除和放射性碘残留消融。
  • 其中64例接受放射性碘治疗,采用单因素和多因素时间-事件分析评估放射性碘对无进展生存和总生存的影响。

主要发现

  • 中位随访5.7年期间,27例患者出现疾病进展,13例死亡。
  • 促甲状腺激素抑制下甲状腺球蛋白≥1 ng/ml且接受放射性碘治疗的患者,无进展生存(Log-rank p=0.001)和总生存(p=0.005)优于未治疗患者。
  • 促甲状腺激素抑制下甲状腺球蛋白<1 ng/ml的患者中未观察到放射性碘治疗的效果。
  • 总生存仅与年龄和促甲状腺激素抑制下甲状腺球蛋白显著相关(HR 8.31,95%CI 1.56-44.3,p=0.01)。

关键数值与推荐

  • 无进展生存的多因素分析:促甲状腺激素抑制下甲状腺球蛋白≥1 vs <1 ng/ml,HR 18.2(95%CI 5.09-64.8,p=0.001)。
  • 总生存的多因素分析:年龄和促甲状腺激素抑制下甲状腺球蛋白(HR 8.31,95%CI 1.56-44.3,p=0.01)显著相关。
  • 总生存的多因素分析:放射性碘治疗是 vs 否,HR 0.34(95%CI 0.1-1.15,p=0.08)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose as to evaluate the impact of adjuvant radioactive iodine therapy (RAI) on prognosis, as assessed by progression-free survival (PFS) and overall survival (OS), in patients affected by differentiated thyroid carcinoma (DTC) lymph-node relapse and previously treated with lymphadenectomy. METHODS: We retrospectively evaluated DTC patients treated with lymph-node dissection for disease relapse. All patients had previously undergone total thyroidectomy and radioiodine remnant ablation (RRA). We used clinical and histological data obtained during follow-up to assess response and outcome. By means of univariate and multivariate time-to-event analyses, we assessed the impact of RAI on outcome (PFS and OS) and the prognostic role of thyroglobulin (Tg) levels under suppression with levothyroxine (Tg-on) measured 1-3 months after lymphadenectomy and of other risk factors. RESULTS: We evaluated 113 patients (age at diagnosis: median 41 years, interquartile range: 31-59), 64 of whom were treated with RAI. Over a median follow-up time of 5.7 years, 27 patients showed disease progression and 13 died. Kaplan-Meier PFS and OS curves showed that age on diagnosis, tumor histology, tumor size, DTC aggressive variant, and Tg-on were associated with prognosis. Patients with Tg-on ≥1 ng/ml treated with RAI showed a better PFS (Log-rank pp 0.001) and OS (p = 0.005) than untreated patients, while no effect of RAI was observed in patients with Tg-on <1 ng/ml. Multivariate models showed that age, Tg-on (≥1 vs. < 1 ng/ml, HR: 18.2, 95% CI: 5.09-64.8, p = 0.001) and RAI (Yes vs. No, HR: 0.36,95%CI: 0.15-0. 9, p = 0.02) remained the only independent factors associated with PFS, but only age and Tg-on remained significantly associated with OS (HR: 8.31, 95%CI:1.56-44.3, p = 0.01). Nonetheless, patients treated with RAI showed a lower risk of mortality (HR: 0.34, 95%CI: 0.1-1.15 p = 0.08) than untreated patients. CONCLUSIONS: RAI after lymphadenectomy for DTC relapse is significantly associated with better PFS only in patients with Tg-on ≥1 ng/ml.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Piccardo A, Puntoni M, Bottoni G, et al. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy. Eur J Nucl Med Mol Imaging. 2016. PMID: 27966046. doi:10.1007/s00259-016-3593-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。